SOURCE-LINKED STUDY SUMMARY
Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a).
What was studied?
Two studies examined anabolic-steroid exposure and blood lipids: an unblinded comparison of self-selected users and nonusers, and a randomized, double-blind nandrolone-versus-placebo trial.
What changed?
Self-selected steroid use was associated with HDL falling from 1.08 to 0.43 mmol/l and Apo-B rising from 0.96 to 1.32 g/l. Several changes persisted six weeks after stopping. Total cholesterol and triglycerides were unchanged. Nandrolone did not change HDL or Apo-B; lipoprotein(a) declined in both trial groups and returned to baseline after withdrawal.
Who was studied?
The observational study included 19 steroid users and 16 nonusers, all healthy male strength athletes. The randomized trial involved 16 bodybuilders.
Studied exposure
Users self-administered steroids for eight or 14 weeks. The trial tested intramuscular nandrolone decanoate, 200 mg/week for eight weeks, against placebo.
What remains uncertain?
The effect of nandrolone-related lipoprotein(a) changes on atherosclerosis remains unestablished. Lipid-marker changes alone do not demonstrate cardiovascular benefit.
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1136/bjsm.2003.000199